Sosman JA - Search Results

1

Update on the targeted therapy of melanoma.

Johnson DB, Sosman JA. Johnson DB, et al. Among authors: sosman ja. Curr Treat Options Oncol. 2013 Jun;14(2):280-92. doi: 10.1007/s11864-013-0226-8. Curr Treat Options Oncol. 2013. PMID: 23420410 Free PMC article. Review.

2

CI-980 in advanced melanoma and hormone refractory prostate cancer.

Ryan CW, Shulman KL, Richards JM, Kugler JW, Sosman JA, Ansari RH, Vokes EE, Vogelzang NJ. Ryan CW, et al. Among authors: sosman ja. Invest New Drugs. 2000 May;18(2):187-91. doi: 10.1023/a:1006382014403. Invest New Drugs. 2000. PMID: 10857996 Clinical Trial.

3

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK; Southwest Oncology Group. Sosman JA, et al. J Clin Oncol. 2002 Apr 15;20(8):2067-75. doi: 10.1200/JCO.2002.08.072. J Clin Oncol. 2002. PMID: 11956267 Clinical Trial.

4

Melacine: an allogeneic melanoma tumor cell lysate vaccine.

Sosman JA, Sondak VK. Sosman JA, et al. Expert Rev Vaccines. 2003 Jun;2(3):353-68. doi: 10.1586/14760584.2.3.353. Expert Rev Vaccines. 2003. PMID: 12903801 Review.

5

Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy.

Sosman JA. Sosman JA. J Am Soc Nephrol. 2003 Nov;14(11):2695-702. doi: 10.1097/01.asn.0000091589.10594.66. J Am Soc Nephrol. 2003. PMID: 14569078 Review.

6

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.

Sondak VK, Sosman JA. Sondak VK, et al. Among authors: sosman ja. Semin Cancer Biol. 2003 Dec;13(6):409-15. doi: 10.1016/j.semcancer.2003.09.004. Semin Cancer Biol. 2003. PMID: 15001159 Review.

7

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.

Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. Amiri KI, et al. Among authors: sosman ja. Cancer Res. 2004 Jul 15;64(14):4912-8. doi: 10.1158/0008-5472.CAN-04-0673. Cancer Res. 2004. PMID: 15256463

8

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.

Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA. Wyman K, et al. Among authors: sosman ja. Cancer. 2006 May 1;106(9):2005-11. doi: 10.1002/cncr.21834. Cancer. 2006. PMID: 16565971 Clinical Trial.

9

Innovations and challenges in melanoma: summary statement from the first Cambridge conference.

Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Atkins MB, et al. Among authors: sosman ja. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2291s-2296s. doi: 10.1158/1078-0432.CCR-05-2560. Clin Cancer Res. 2006. PMID: 16609047

10

Molecular targets in melanoma from angiogenesis to apoptosis.

Sosman JA, Puzanov I. Sosman JA, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2376s-2383s. doi: 10.1158/1078-0432.CCR-05-2558. Clin Cancer Res. 2006. PMID: 16609062 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results